EA025831B1 - Композиции из hyr1-производных и способы лечения ими - Google Patents

Композиции из hyr1-производных и способы лечения ими Download PDF

Info

Publication number
EA025831B1
EA025831B1 EA201391199A EA201391199A EA025831B1 EA 025831 B1 EA025831 B1 EA 025831B1 EA 201391199 A EA201391199 A EA 201391199A EA 201391199 A EA201391199 A EA 201391199A EA 025831 B1 EA025831 B1 EA 025831B1
Authority
EA
Eurasian Patent Office
Prior art keywords
zeg
protein
azr
azp
polypeptide
Prior art date
Application number
EA201391199A
Other languages
English (en)
Russian (ru)
Other versions
EA201391199A1 (ru
Inventor
Ашраф С. Ибрагим
Майкл Р. Йиман
Джон Е. Джр. ЭДВАРДС
Гуаньпиншэн Ло
Юэ ФУ
Original Assignee
Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер filed Critical Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер
Publication of EA201391199A1 publication Critical patent/EA201391199A1/ru
Publication of EA025831B1 publication Critical patent/EA025831B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201391199A 2011-09-14 2012-09-14 Композиции из hyr1-производных и способы лечения ими EA025831B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161534734P 2011-09-14 2011-09-14
US201161564201P 2011-11-28 2011-11-28
PCT/US2012/055604 WO2013040478A2 (en) 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same

Publications (2)

Publication Number Publication Date
EA201391199A1 EA201391199A1 (ru) 2014-04-30
EA025831B1 true EA025831B1 (ru) 2017-02-28

Family

ID=47884005

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391199A EA025831B1 (ru) 2011-09-14 2012-09-14 Композиции из hyr1-производных и способы лечения ими

Country Status (11)

Country Link
US (1) US10160790B2 (https=)
EP (1) EP2755668A4 (https=)
JP (1) JP2014527084A (https=)
CN (1) CN103998049A (https=)
AU (1) AU2012308281A1 (https=)
BR (1) BR112014005773A2 (https=)
CA (1) CA2848403A1 (https=)
EA (1) EA025831B1 (https=)
GE (2) GEP20197052B (https=)
UA (1) UA115305C2 (https=)
WO (1) WO2013040478A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP2942389A1 (en) * 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
GB201503812D0 (en) * 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
CN108472372B (zh) * 2015-07-13 2022-05-17 海港医学中心洛杉矶生物医学研究所 结合不动杆菌的抗体结合剂及其用途
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
GB201902769D0 (en) * 2019-03-01 2019-04-17 Univ Court Of The Univ Of Aberdeen Antibody molcules and uses thereof
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
WO2011003085A1 (en) * 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
WO2011003085A1 (en) * 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHOI et al. Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. BMC Microbiol. 2008, Vol. 8: 216. PDF file: pg. 1-11, Abstract, pg. 2, middle para, pg. 3, Fig. 1, and pg. 9, col. 1, last para *
KRAMER et al. How longido nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect. Dis. 2006, Vol. 6:130 PDF file pg. 1-8, Abstract, pg. 2, para 2, pg. 3, col. 1, para 2, pg. 4, col. 1, last para, Fig. 1, and Table 2, and pg. 5, col. 1, middle para and last para *
NCBI_YP_001084998, putative outer membrane protein [Acinetobacter baumannii ATCC 17978] 29 May 2010 [online]. [Retrieved on 2012.11.27]. Retrieved from the Internet <URL:http//www.ncbi.nlm.nih.gov/protein/126642014?sat=14&satkey=11569880> Definition, and Reference *
PELEG et al. Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA. 2008, vol. 105(38), p. 14585-90. Entire documentation, especially Abstract *
SMITH et al. New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes Dev. 2007, Vol. 21(5), p. 601-14 pg. 605, Fig. 3, pg. 608, Table 1, and pg. 613, col. 1, para 4 *
SOARES et al. 2-DE analysis indicates that Acinetobacter baumannii displays a robust and versatile metabolism. Proteome Sci. 2009, Vol. 7:37. PDF file: pg. 1-10. Abstract; and pg. 6, para 1 *

Also Published As

Publication number Publication date
GEAP201913226A (en) 2019-07-10
UA115305C2 (uk) 2017-10-25
EP2755668A4 (en) 2015-07-01
CN103998049A (zh) 2014-08-20
BR112014005773A2 (pt) 2019-09-24
WO2013040478A2 (en) 2013-03-21
US20150191514A1 (en) 2015-07-09
WO2013040478A3 (en) 2013-06-27
AU2012308281A1 (en) 2014-04-24
EA201391199A1 (ru) 2014-04-30
US10160790B2 (en) 2018-12-25
JP2014527084A (ja) 2014-10-09
CA2848403A1 (en) 2013-03-21
EP2755668A2 (en) 2014-07-23
GEP20197052B (en) 2019-12-25

Similar Documents

Publication Publication Date Title
EA025831B1 (ru) Композиции из hyr1-производных и способы лечения ими
EP1379552B2 (en) Toll-like receptor 5 ligands and methods of use
KR101748453B1 (ko) 폐렴구균(Ｓｔｒｅｐｔｏｃｏｃｃｕｓ Ｐｎｅｕｍｏｎｉａｅ)에 대항하는 백신과 조성물
CN103998056B (zh) 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
ES2445399T3 (es) Vacuna para la prevención de la recaida del cáncer de mama
Portuondo et al. A cell wall protein-based vaccine candidate induce protective immune response against Sporothrix schenckii infection
CN101107009B (zh) 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
US20190256562A1 (en) Group a streptococcus vaccine
EP2968497B1 (en) Compositions and methods for treating fungal and bacterial pathogens
CN114423448A (zh) 疫苗组合物和选择抗原的方法
JP2021522239A (ja) 熱ショックタンパク質結合ペプチド組成物およびその使用方法
US11413336B2 (en) Coccidioides antigens and methods of their use
WO2020096046A1 (ja) 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
US9926342B2 (en) Recombinant VapA and VapC peptides and uses thereof
AU2016263534A1 (en) Treatment and detection of trypanosomes
CN117979992A (zh) 钩端螺旋体毒力调节蛋白及其用途
WO2014144222A2 (en) Compositions and methods of treating fungal and bacterial pathogens
TW201929896A (zh) 用於常在病原疾病進展之全面性疫苗設計
TW201823267A (zh) 瘧疾疫苗
US20030229454A1 (en) Use of a computer to design a molecule
CN103539840B (zh) 表皮生长因子受体模拟表位肽及其应用
US20190328854A1 (en) C5 immunization for autologous anti-c5 antibody production
WO2025219610A1 (en) A vaccine for the treatment or prevention of pseudomonas aeruginosa infection in a subject.
HK40106181A (zh) 鈎端螺旋体毒力调节蛋白及其用途
JP5534630B2 (ja) Ｇｄ３模倣ペプチド

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU